The management of onychomycosis;Traitement des onychomycoses

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 12 II, 2003, Pages 1260-1271

  Baran, R ^a   Richert, B ^b  

^a Ctr diagn/traitem maladies ongles   (France)

^b Serv Dermatol   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTACID AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ASTEMIZOLE; CHLORDIAZEPOXIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLOPIROX; CICLOPIROXOLAMINE; CORTICOSTEROID; CYCLOSPORIN A; FLUCONAZOLE; GRISEOFULINE; GRISEOFULVIN; HYPOCHLORITE SODIUM; IMIDAZOLE; INSULIN; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MYCOLOG; OMEPRAZOLE; PAINT; PEVISONE; PHENYTOIN; POVIDONE IODINE; RIFAMPICIN; SPASMOLYTIC AGENT; SULFONYLUREA; TERBINAFINE; TERFENADINE; TROSIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ADVERSE DRUG REACTION; AGRANULOCYTOSIS; ARTICLE; BLOOD TOXICITY; DEBRIDEMENT; DESQUAMATION; DIARRHEA; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FATALITY; DRUG MECHANISM; DRUG POTENCY; DYSPEPSIA; ECONOMIC ASPECT; ECZEMA; EOSINOPHILIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; NAUSEA; NEUTROPENIA; NONHUMAN; ONYCHOMYCOSIS; PRURITUS; RASH; SKIN ALLERGY; SKIN MANIFESTATION; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; URTICARIA; VOMITING;

ANTIFUNGAL AGENTS; HUMANS; ONYCHOMYCOSIS;

EID: 0346154796     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. e éd. Londres. Martin Dunitz-Taylor and Francis 2003;chap 8:143-158.
2. Feuilhade de Chauvin M, Baran R, Chabasse D. Les onychomycoses III. Traitement. J Mycol Med 2001;11:205-15.
3. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease free nail. Arch Dermatol 1999;134:1551-4.
4. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Safety 2000;22:33-52.
5. Chabasse D, Baran R, Feuilhade de Chauvin M. Les onychomycoses I. Epidemiologie-étiologie. J Mycol Med 2000;10:177-90.
6. Delevoux M. Griséofulvine. Ann Dermatol Venereol, 2001;128:1317-25.
7. Bennett ML, Fleisher AB, Loveless JW, Feldman SR. Oral griseofulvine remains the treatment of choice of Tinea capitis in Children. Ped Dermatol 2000;17:304-9.
8. Piérard GE, Arrese-Estrada J, Piérard-Franchimont C. Treatment of onychomycosis: traditional approach. J Am Acad Dermatol 1993;29:S41-5.
9. Gupta AK, Scher RK. Oral antifungal agents for onychomycosis. Lancet 1998;351:541-2.
10. Svegaard E. Oral ketoconazole as an alternative to griseofulvine in recalcitrant dermatophytes infections and onychomycosis. Acta Dermatol 1985;65:143-9.
11. Hofmann H, Brautigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis. A randomized double-blind study with terbinafine and griseofulvine. Lagos II study Group. Arch Dermatol 1995;131:919-22.
12. Faergemann J, Anderson C, Hersle K, Hradil E, Nordin P, Kaaman T, et al. Double-blind, parallel group comparison of terbinafine and griseofulvine in the treatment of toenail onychomycosis. J Am Acad Dermatol 1996;32:750-3.
13. Iozumi K, Hattori N, Adachi M, Kaneko T, Shimozuma M, Tamaki K. Long-term follow-up study of onychomycosis: cure rate and dropout rate with antifungal treatments. J Dermatol 2001;28:128-36.
14. Botter AA, Dethier F, Mertens RLJ, Morias J, Perremans W. Skin and nail mycoses: treatment with ketoconazole a new oral antimycotic agent. Mykosen 1979;22:274.
15. Brodell RT, Elewski BE. Clinical pearl: systemic antifungal drugs and drug interactions. J Am Acad Dermatol 1995;33:259-60.
16. Knight TE, Shikuma CY, Knight J. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 1991;25:398-400.
17. Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Med Int 1984;144:1069-70.
18. Chien RN, Yang LJ, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997;25:103-7.
19. Daniel CR. Traditional management of onychomycosis. J Am Acad Dermatol 1996;35:S21-25.
20. Hargreaves GK. The treatment of onychomycosis with griseofulvine. Br J Dermatol 1960;72:358-64.
21. Baran R, Hay R. Partial surgical avulsion of the nail in onychomycosis. Clin Exp Dermatol 1985;10:413-8.
22. Mackey-Wiggan J, Elewski BE, Scher RK. The diagnosis and treatment of nail disorders: systemic antifungal therapy. Dermatologic Therapy 2002;15:78-88.
23. Katz H. Systemic antifungal agents to treat onychomycoses. J Am Acad Dermatol 1998;38:S48-52.
24. De Doncker PR, Scher RK, Baran RL, Decroix J, Degreef HJ, Roseeuw DI, et al. Itraconazole therapy is effective for pedal onychomycoses caused by some nondermatophyte molds and in mixed infection dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997;36:173-7.
25. Gupta AK, Chwetzoff E, Del Rosso J, Baran R. Hepatic Safety of itraconazole. J Cut Med Surg 2002;6:210-3.
26. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766-7.
27. Gupta A, Scher R, Rich P. Fluconazole for the treatment of onychomycosis: an update. J Dermatol 1998;37:815-20.
28. Lebwohl MG, Daniel CR, Leyden J, Mormon M, Shavin JS, Tschen E, et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol 2001;40:358-60.
29. Gupta A, Katz I, Shear N. Drug interactions with itraconazole, fluconazole and terbinafine and their management. J Am Acad Dermatol 1999;41:237-49.
30. Fleckman P. Onychomycosis: diagnosis and topical therapy. Dermatologic Therapy. 2002;15:71-7.
31. Baran R. Amorolfine nail lacquer: A new transungual delivery system for nail mycoses. JAMA 1993;9 (Suppl 4):5-6.
32. Baran R. Dermatopharmacology of Topical Anti-Fungal Preparations in Nail Tissue. In Gabard B, Elsner P, Surber C. Treffel P. (eds) in: Dermato-pharmacology of Topical Preparations. Berlin, Springer, 2000.
33. Haria M, Bryson HM. Amorolfine. Drugs 1995;49:103-20.
34. Marty JP. Amorolfine nail lacquer: A novel formulation. JEADV 1995;4 (suppl 1) S17-S21.
35. Baran R. Nail fungal infections and treatment. Hand Clinics 2002;18:625-8.
36. Gupta A, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43:S70-80.
37. Nolting S, Ulbricht H. Kutersuchungen zur Applikations frequenz von Ciclopirox-lack 8% bei der Behandlung von Onychomycosen. Jatros Derma 1997;11:20-6.
38. Baran R, Gupta AK. Are boosters or supplementation of antifungal drugs of any use for treating onychomycosis? J Drugs Dermatol 2002;1:35-41.
39. Gupta AK, Baran R, Summerbell R. Onychomycosis: strategies to improve efficacy and reduce recurrence. JEADV 2002;16:579-86.
40. Scher R. Onychomycoses: therapeutic update. J Am Acad Dermatol 1999;40:S21-6.
41. Roberts DT, Evans EGV. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998;138:189-90.
42. Hay RJ. Chronic dermatophyte infections. In: Superficial fungal infections. Verbov J (ed) MTP Press Limited, Lancaster (England) 1986, p 23-24.
43. Baran R, de Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol 1996;76:82-3.
44. AkdÄ. Treatment of onychomycosis with terbinafine. Risk of serious skin reactions. Deutches Arzteblatt 1997;94:31-2.
45. Polak-Wyss A. Mechanism of action of antifungals and combination therapy. JEADV 1995;4 (suppl 1):S11-S16.
46. Polak A. The past, present and future of antimycotic combination therapy. Mycoses 1999;42:355-70.
47. Evans EGV. The rationale for combination therapy. Br J Dermatol 2001;145:(Suppl 60):9-13.
48. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol 2001;145:(Suppl 60):15-9.
49. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 2001;145:(Suppl 60):21-6.
50. Goodfield MJD, Evans EGV. Combined treatment with surgery and short duration oral antifungal therapy in patients with limited dermatophyte toenail infection J Dermatol Treat 2000;11:259-62.
51. Gupta AK, Skinner AR, Baran R. Onychomycosis in children: An overview. J Drugs Dermatol 2003;2:31-4.
52. Lestringant GG, Nsanza J, Nada M, et al. Effectiveness of amorolfine 5% nail lacquer in the treatment of long duration Candida onychomycosis with chronic paronychia. J Dermatol Treat 1996;7:89-92.
53. Vander-Straten MR, Balkis MM, Ghannoum MA. The role of nondermatophyte molds in onychomycosis. Diagnosis and treatment. Dermatol Ther 2002;15:89-98.
54. Sigurgeirsson B, Olafson JH, Steinson J, Paul C, Billstein EG, Evans EGV. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis. A 5-year blinded prospective follow-up study. Arch Dermatol 2002;138:353-7.
55. Sigurgeirsson B, Paul C, Curran D, Evans EGV. Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. Br J Dermatol 2002;147:1241-3.
56. Zaias N, Tosti A, Rebell G, Morelli R. Bardazzi F, Bieley H, et al. Autosomal dominant pattern of distal subungual onychomycosis. J Am Acad Dermatol 1996;34:302-4.
57. Nardi L. Onychomycose des orteils: aspects diagnostiques et stratégies thérapeutiques. Rev Med Travail 1995;22:83-6.